Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Immunomodulating drugs in myelodysplastic syndromes

    ... drug (IMID) thalidomide and its derivative lenalidomide (LEN) have been used in MDS, principally in lower-risk MDS. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Combination strategies in myelodysplastic syndromes.

    ... International Prognostic Scoring System . Currently, lenalidomide , azacitidine , and decitabine are the only ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. An update on the treatment of myelodysplastic syndromes.

    ... MDS, the novel antitumor immunomodulatory agent lenalidomide is approved for patients with del(5q), and two different ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Myelodysplastic syndromes.

    ... diagnosis is 72 and the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... azacitidine , (2) decitabine , and (3) lenalidomide . Clinical results with each of these agents, plus results ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Myelodysplastic syndromes in older adults.

    ... from curative treatment. Developments using the drugs lenalidomide , decitabine , and azacitidine have offered ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Current and future management options for myelodysplastic syndromes.

    ... and (ii) the emergence of US FDA-approved agents such as lenalidomide , azacitidine and decitabine . Prior to these ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Azacytidine for the treatment of myelodysplastic syndromes in the elderly.

    ... observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacytidine (5-AZA) for ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... of patients with MDS: immunomodulatory agents ( lenalidomide ), and hypomethylating therapy [HMT ( decitabine and ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... risk and no transfusion dependency, growth factors, and lenalidomide for patients with alteration of chromosome 5 and anemia ...

    Research Article last updated 07/20/2018 - 5:14pm.